Nouri Market Research

The GLP-1 companion supplement opportunity in AU/NZ is real, quantified, and uncontested — a 12–18 month window before AU incumbents and Hims & Hers / Eucalyptus close it. Australia: ~500,000 active GLP-1 users, ~180,000–240,000 paying AUD $4–5K/year out-of-pocket. New Zealand: ~62,000 Wegovy users, all private-pay since July 2025. Clinical research confirms 98.6% of GLP-1 patients fall below the vitamin D DRI and 39–45.5% of their weight loss is lean muscle — yet no dedicated companion supplement brand operates in either market today.